I think you're correct about Keppra. On its own it not much to make a deal for. But, I do see it packaged in along with others that a partner might be interested.
Either way, approval on additional ANDAs are good none the less. It be amazing if we can get most of all ANDAs approved by end of year. Odidi would be in a very good negotiating position with all these drugs ready to go.
I also get the feeling that they may continue ANDA pipe line since the conditions with FDA approval have changes going forward. The recent Ranexa filing is an indication that they aren't dropping the ANDA pipeline and we may see more being filed.
Remember IPCI started down the ANDA path way, the only reason they switch to NDA is because of FDA delays. Now the situation with FDA is looking better with Keppra, Seroquel, and Glucophage approval it is clear things are changing in favor of IPCI.
I am seriously considering increasing my holding here. Sold a bunch of my Nvidia shares not long ago.
News 
Market Data 
Discover 
AI
